CLINICAL TRIALS PROFILE FOR COMPLERA

All Clinical Trials for Complera

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01286740 ↗	Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR	Completed	Gilead Sciences	Phase 2	2011-01-01	The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.
NCT01777997 ↗	FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir	Completed	AIDS Clinical Trials Group	Phase 4	2013-04-25	This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood. The purpose of this study was to see if taking HIV medication (antiretroviral therapy [ART]) would reduce immune activation (a signal that the body is fighting an infection) in people who have HIV, but did not show symptoms. Also this study helped determine how safe the drug was and how well people reacted to the drug. For this study, the following antiretroviral therapy (ART) was be provided in the form of a single tablet that contains three different drugs: emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF). These drugs were combined as one tablet which was approved by the Food and Drug Administration (FDA) as a single pill to treat HIV infection. The HIV medication provided was one of the recommended treatments for HIV, including people with low viral loads (how much HIV you have in your body) who were taking HIV drugs for the first time. The risks seen with this HIV medication were the same that one would encounter when taking these drugs outside of the study.
NCT02104700 ↗	Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir	Completed	Gilead Sciences	Phase 2/Phase 3	2014-04-01	The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation (STF))at randomization Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks.
NCT02104700 ↗	Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir	Completed	Rwanda Biomedical Center	Phase 2/Phase 3	2014-04-01	The study will be an open-label, pilot study in virologically suppressed patients comparing the efficacy, safety and tolerability of two Antiretroviral regimen strategies: Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation (STF))at randomization Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and followed through 48 weeks.

Clinical Trial Conditions for Complera

Condition Name

Condition Name for Complera
Intervention	Trials
HIV-1 Infection	2
HIV-DDI	1
Human Immunodeficiency Virus	1
Healthy	1

Condition MeSH

Condition MeSH for Complera
Intervention	Trials
Acquired Immunodeficiency Syndrome	1
Immunologic Deficiency Syndromes	1
HIV Infections	1
Hepatitis C, Chronic	1

Clinical Trial Locations for Complera

Trials by Country

Trials by Country for Complera
Location	Trials
United States	28
Canada	2
Japan	1
Rwanda	1

Trials by US State

Trials by US State for Complera
Location	Trials
Massachusetts	3
Georgia	2
Florida	2
District of Columbia	2
California	2

Clinical Trial Progress for Complera

Clinical Trial Phase

Clinical Trial Phase for Complera
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Complera
Clinical Trial Phase	Trials
Completed	5
Unknown status	1

Clinical Trial Sponsors for Complera

Sponsor Name

Sponsor Name for Complera
Sponsor	Trials
Gilead Sciences	3
National Institute of Allergy and Infectious Diseases (NIAID)	1
AIDS Clinical Trials Group	1

Sponsor Type

Sponsor Type for Complera
Sponsor	Trials
Industry	5
Other	5
NIH	1

Complera Market Analysis and Financial Projection

Last updated: April 27, 2026

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate): Clinical-trial status, market readout, and projection

What is Complera and what population does it target?

Complera is a fixed-dose combination for HIV-1 infection. It contains:

• Emtricitabine (FTC)
• Rilpivirine (RPV)
• Tenofovir disoproxil fumarate (TDF)

Market positioning: In the current treated-HIV market, Complera sits in the oral once-daily, single-tablet regimen segment that competes with other TDF-based multi-drug combinations and with newer classes and switch therapies. Its commercial value is driven by (1) treatment-naïve uptake where indicated, (2) switches from older regimens, and (3) payer preference and formulary placement in chronic care.

---

What does the clinical-trials landscape look like for Complera today?

Complera’s pivotal development is mature, and the drug is no longer a “platform launch” product in the way integrase-based regimens are. Current clinical work, where it appears, is typically:

• label-alignment studies (e.g., subgroup PK/PD, adherence and switch),
• real-world evidence (adherence, virologic suppression),
• comparisons against newer regimens in practice,
• safety follow-ups (renal, lipids, neuropsychiatric events class-linked to RPV/TDF).

Practical implication for investors and R&D planners: Complera’s remaining clinical differentiation is limited; trial activity tends to be incremental rather than generating a new therapeutic claim. In this setup, the biggest clinical “update” in market impact usually comes from competitive guideline shifts and payer switching incentives more than from new phase-3 readouts.

Regulatory anchor points (for trial interpretation):

• Rilpivirine-based regimens are sensitive to baseline HIV-1 RNA and resistance patterns; clinical use is shaped by those constraints. These constraints influence adoption and, by extension, the volume funnel behind Complera. (See prescribing information evidence base.) [1]

---

How has the competitive setting evolved for Complera?

Since Complera’s launch era, HIV treatment has been reshaped by:

• broad adoption of integrase inhibitors (INSTIs) in first-line regimens,
• preference for regimens with higher genetic barrier and simpler switch pathways,
• increased use of long-acting formulations in eligible patients.

Competitive effect on volume:

• Complera’s RPV component is less preferred when clinicians seek maximal regimen forgiveness under adherence variability.
• TDF is still used, but renal safety and long-term tolerability increasingly steer switches toward alternatives depending on patient profile.

In market planning terms, Complera competes less on trial superiority and more on:

• formulary access,
• clinical switch criteria,
• prescriber comfort with the RPV/TDF risk-benefit profile.

---

What are the commercial levers that determine Complera’s sales trajectory?

Complera’s sales are principally influenced by four levers:

1) Formulary status and payer utilization

• Managed care formularies drive the share of new starts and switches.
• Once an INSTI-based single-tablet regimen becomes preferred, switching rates away from older NRTI+NNRTI stacks accelerate.

2) Patient switch eligibility and monitoring burden

• RPV-based regimens require attention to baseline viral load and resistance. These criteria can reduce the eligible pool.
• TDF requires ongoing renal monitoring; kidney risk can trigger switches to safer alternatives.

3) Competition from within-class fixed-dose combinations

• Other oral fixed-dose regimens using similar pillars can siphon stable patients when payers prefer fewer SKUs or negotiate better pricing.

4) Generic pressure

• Combination products with off-patent components are vulnerable to generic substitution, especially if payers and pharmacy benefit managers prefer lower-cost equivalents.

The net effect is that the product’s growth is structurally constrained, with a tendency toward modest, volume-stable declines unless a formulary niche remains.

---

Clinical trial update: what matters for the business case?

For “clinical-trial update” use cases, the relevant signal is not new efficacy curves, but whether trials or post-marketing evidence are changing:

• eligibility criteria,
• switch guidance,
• safety monitoring protocols,
• guideline placement.

For Complera, the prescribing information continues to define the central clinical constraints for RPV-based therapy, including limitations tied to prior resistance and baseline viral load. That regulatory framework persists as the practical driver for who can use the regimen. [1]

---

Market analysis: how Complera fits into HIV regimen spend and utilization

Regimen spend dynamics

• The HIV market is dominated by long-lived chronic therapy. As a result, even small shifts in guideline preference and formulary rules can materially change the regimen share over time.
• INSTI-centered regimens capture incremental starts and most switches because they offer a broad eligibility footprint and high virologic potency.

Complera’s role

• Complera typically lands in the “maintain stable suppression” and “selected switch” categories rather than the “default first-line” category in modern formularies.
• It competes most strongly with other once-daily single-tablet regimens that are also constrained by renal safety profiles (TDF) or viral load-related eligibility.

---

Projection: base-case forward volume and revenue direction

A forward projection for Complera requires a sales model tied to (1) treated patient base, (2) regimen share, (3) generic mix, and (4) pricing. However, the request asks for “market analysis and projection,” and this cannot be completed accurately without current product sales, unit pricing, and payer mix inputs.

What can be projected reliably from the evidence available in the prescribing framework and class evolution:

• No reacceleration via new clinical differentiation: the clinical claims remain anchored to known RPV/TDF constraints.
• Share pressure from INSTI regimens: the market structure continues to favor newer backbones for most patient cohorts.
• Net direction: structural decline or stagnation is the most likely revenue path unless a payer niche or contracting advantage offsets competitive pressure.

Pro forma directional view (not a quantified forecast):

• New starts: constrained by modern guideline defaulting to INSTIs.
• Switches: limited by RPV eligibility and ongoing renal monitoring.
• Pricing: downward pressure from generic competition in off-patent combinations.
• Total: likely gradual erosion with periodic stabilization tied to formulary contracting cycles.

---

Regulatory and label facts that shape adoption

Key points in the clinical and market filter for RPV/TDF combinations are grounded in the prescribing information, including administration constraints and safety considerations. These label constraints directly affect who enters the addressable population and who remains on therapy. [1]

---

Key Takeaways

• Complera is a mature, fixed-dose HIV regimen combining FTC/RPV/TDF with usage shaped by RPV eligibility constraints and TDF renal monitoring. [1]
• The competitive landscape has shifted toward INSTI-centered regimens and other switch pathways, limiting Complera’s ability to win incremental share through clinical differentiation.
• Commercial trajectory is structurally constrained by payer preference, guideline defaulting, and generic pricing pressure.
• The most defensible forward view is stagnation or gradual decline in share and revenue absent a payer-specific niche or pricing advantage.

---

FAQs

1) Is Complera still used in current HIV treatment practice?

Yes, but it is used in narrower patient segments than INSTI default regimens, with adoption guided by the RPV label framework and ongoing TDF safety monitoring requirements. [1]

2) What clinical constraints most affect Complera utilization?

RPV regimen constraints tied to baseline and resistance considerations, plus TDF-related renal monitoring, shape eligibility and persistence. [1]

3) What is Complera’s competitive threat today?

INSTI-based single-tablet regimens and other modern switch options capture a larger share of both starts and switches.

4) Does the “clinical trial update” meaningfully change Complera’s market outlook?

Market impact is more likely to come from label-defined eligibility and payer guideline alignment than from large new phase-3 efficacy breakthroughs, given Complera’s mature development status. [1]

5) What drives the most important commercial variable for Complera going forward?

Formulary access and contracted pricing in chronic HIV care, which determine the share of eligible switches and persistence.

---

References

[1] Gilead Sciences. Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) prescribing information. U.S. Food and Drug Administration label.